Non-Hodgkin lymfoom Mark-David Levin.

Slides:



Advertisements
Verwante presentaties
Non-Hodgkin-lymfoom Afdeling Hematologie
Advertisements

Autologe stamceltransplantatie
Trombose Kanker Antistolling
De ziekte van Waldenström en het lymfoplasmacytaire lymfoom
SCEPTRE symposium, 29 januari 2009
Acute lymfatische leukemie (ALL)
NEOADJUVANTE CHEMOTHERAPIE
Chronische lymfatische leukemie
Een patiënt met een DLBCL (diffuus grootcellig B-cellymfoom)
R. Boersma/A. Demandt MUMC+
Mustafa Dönmez AIOS interne-oncologie Erasmus MC
DE KLIMOPSTUDIE OUDEREN EN KANKER
Pelsser-Voeding en Gedrag-dieet als behandeling van ADHD
28 januari 2009 Auditieve mogelijkheden en taalontwikkeling bij kinderen met CI op de langere termijn Margreet Langereis Anneke Vermeulen.
Acute myeloïde leukemie (AML)
“In de kern gezond” Buurtcafé Gezondheidscentrum America.
geneesmiddel geïnduceerde morbiditeit en mortaliteit
Opportunistische infecties ten tijde van antiretrovirale therapie
Laaggradig lymfoom Patient casus: Dhr Y. 67 jaar
Minimal Residual Disease bepaling bij CLL
Ileus bij gemetastaseerde ziekte: is er een perspectief
Moet levodopa-behandeling zo lang mogelijk uitgesteld worden in de ziekte van Parkinson? Zijn agonisten beter in het vroege stadium? Is levodopa neurotoxisch?
Laaggradig Folliculair Non-Hodgkin Lymfoom
Psychose als bijwerking van ritalin
PICO Sabine Roza 25 januari 2011
Effectiviteit TCAs versus MAOIs
Aripiprazol additie om overgewicht als bijwerking van olanzapine gebruik tegen te gaan Marlijn Vermeiden.
The new Imelda rea-concept for Out of Hospital Cardiac arrest
Carotis stenting Man, 73 jaar
Schokken na reanimatie
Veel studies verricht naar effect van verschillende operatietechnieken. Veel studies verricht naar outcome van operatie : globaal 85 % goed effect v.
Man, 36 jaar 2 weken geleden: kortdurend,onhandige Li arm / hand, woordvindstoornissen.
Patiëntdemonstratie Anton de louw
Amitryptiline bij spanningshoofdpijn
Longtransplantatie en CF
CONSERVATIEVE BEHANDELING MAAGPERFORATIE
Samenvatting meta-analyse over waarde van laparoscopisch behandeling van maagperforatie Drs M. Golghesaei.
Deeg HJ et al. Allogeneic hematopoietic stem cell transplantation of myelofibrosis. Blood 2003,102,3912 IMF- clonale ziekte van beenmergstamcel %
Hodgkin-lymfoom Afdeling Hematologie
Hairy cell leukemie (HCL) ‘pluizebolleukemie’
3e NKI/AvL Mammacarcinoom Symposium “Neoadjuvante Chemotherapie”
Psychotherapie bij persoonlijkheidsstoornissen: bewezen effectief?
Therapie & Prognose Dr. A. Janssen.
METEX studie Methotrexaat versus expectatief beleid bij vrouwen met een EUG NM van Mello arts-onderzoeker.
Family History Is a Predictor for Appendicitis in Adults in the Emergency Department Michael J. Drescher ea. West J Emerg Med December; 13(6): 468–471.
Kenmerken van de huurmarkt in Vlaanderen
MabThera® (rituximab)
AL amyloidose oorzaak, klachten en behandeling
Multipel myeloom: therapie
Hodgkin lymfoom Blok 4 oncologie, oktober 2011
PROSPECTIVE FASE-II TRIAL EVALUATING THE OUTCOME OF INDUCTION CHEMOTHERAPY FOLLOWED BY ePLND AND CHEMORADIATION FOR HIGH RISK INVASIVE BLADDER CANCER.
Risk of Ischaemic Events (CAPRIE). Lancet 1996;348:
Mevr W., geboren in klieren in de hals;langzaam groter
De (Moleculaire)biologie van Maligne Lymfomen Blok oncologie, April 2012 Prof. Dr. Steven Pals, afdeling Pathlogie AMC
MANTELZORGQUIZ.
Nieuwe ontwikkelingen NHL Henriette Berenschot,
DUOS : N=26; Aanmelden: Werkgroep Invasief UC Pieter van den Berg (internist-oncoloog, Tergooiziekenhuizen), Andre Bergman (internist-oncoloog,
Allogene stamceltransplantatie Corrie Bezemer Coördinator hematologie afdeling B3.
Acute myeloide leukemie Mark-David Levin. Acute leukemie { Lowenberg B et al. N Engl J Med 1999;341: , Kaushansky K. N Engl J Med 2006;354:
PICO P: status na okselkliertoilet (bij mammaCa) I: wel bloedafname/infuus plaatsen C: geen bloedafname/infuus plaatsen O: meer risico op infecties/complicaties?
Carotis stenting Man, 73 jaar
Vraag 1 Wat zijn de belangrijkste ontwikkelingen van de afgelopen 10 jaar die de inzichten in de kliniek hebben veranderd?
Beleid bij recidief/gemetastaseerd endometriumcarcinoom
Hematologie update voor de huisarts
Minisymposium Diagnostiek en behandeling van Lymfomen 22 april 2013
Ontwikkeling asbestkanker
Topics in Hematology Benign hematology Hemato-Oncology
Bijwerkingen: CAR-T cel behandeling
De PAULIEN-studie Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC 20 JUNI 2019.
Transcript van de presentatie:

Non-Hodgkin lymfoom Mark-David Levin

Hemato-poiese Normaal Kaushansky K. N Engl J Med 2006;354:2034-2045

Lymfomen 85% 15% Non-Hodgkin lymfoom Hodgkin lymfoom Kaushansky K. N Engl J Med 2006;354:2034-2045

NOOIT DIAGNOSE OP PUNCTIE, ALTIJD BIOPT!! Lymfomen Non-Hodgkin lymfoom 85% NOOIT DIAGNOSE OP PUNCTIE, ALTIJD BIOPT!! Hodgkin lymfoom 15% Kaushansky K. N Engl J Med 2006;354:2034-2045

Hemato-poiese Normale lymfklier

Hemato-poiese Normale lymfklier Diffuus Grootcellig NHL

BM-morfologie

BM-immuno

Non-Hodgkin lymfoom - biopt

Cytogenetica (FISH)

Intermediair NHL - IPI IPI Age adjusted IPI (aaIPI) Ship. A predictive model for aggressive Non-Hodgkin’s lymphoma NEJM 1993; 329: 987

Intermediair NHL - Age adjusted IPI Plateau!

Intermediair NHL - therapie (1999) 1e lijn: 8 x CHOP elke 3 weken genezingskans 50% Bij recidief: 3 x DHAP (klinisch 5 dagen) Autologe stamceltransplantatie na BEAM Genezingskans 25% (grote selectie!)

Intermediar NHL - Rituximab Antistof gericht tegen CD20 = antigeen op alle B-cellen Monotherapie slechts tijdelijke respons Kosten 5.000 - 10.000 Euro per kuur per patient Bijwerking: koorts / rilling tijdens infusie

Rituximab bij jongeren met intermediar NHL 823 patienten met DLBC-NHL < 65 jaar chemo +/- Rituximab Pfreundschuh M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial ... Lancet Oncol. 2006 May;7(5):379-91

Rituximab bij ouderen met intermediar NHL 399 patienten met DLBC-NHL > 65 jaar Event-free survival Coiffier B. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.

Rituximab bij ouderen met intermediar NHL Overleving

Microarray

DLBC-NHL: Gen-expressie profiel Figure 1. Subgroups of Diffuse Large-B-Cell Lymphoma According to Gene-Expression Profiles. Panel A shows the hierarchical clustering of diffuse large-B-cell lymphomas from 240 patients with untreated disease and 34 patients who had previously been treated or who had a preexisting low-grade lymphoma, according to the level of expression of 100 genes. Red areas indicate increased expression, and green areas decreased expression. Each column represents a single diffuse large-B-cell lymphoma, and each row represents a single gene. Genes that are characteristically expressed in germinal-center B-cell-like diffuse large-B-cell lymphomas or activated B-cell-like diffuse large-B-cell lymphomas are indicated. The dendrogram at the top shows the degree to which each diffuse large-B-cell lymphoma is related to the others with respect to gene expression. Panel B shows the number of samples with amplification of the c-rel locus and bcl-2 translocations in subgroups of diffuse large-B-cell lymphoma. The ratio of genomic copy number for the c-rel and {beta}2-microglobulin loci was determined by a quantitative polymerase-chain-reaction assay, and ratios greater than 2 were considered to indicate c-rel amplification. The bcl-2 translocations were detected with the use of a polymerase-chain-reaction assay for the main break-point cluster region that is frequently involved in the t(14;18) translocation. Data are from patients who had untreated diffuse large-B-cell lymphomas without preexisting cancer. Panel C shows Kaplan-Meier estimates of overall survival after chemotherapy among the 240 previously untreated patients, according to the gene-expression subgroup. Rosenwald A et al. N Engl J Med 2002;346:1937-1947

Gen-expressie profiel DLBC-NHL Figure 1. Subgroups of Diffuse Large-B-Cell Lymphoma According to Gene-Expression Profiles. Panel A shows the hierarchical clustering of diffuse large-B-cell lymphomas from 240 patients with untreated disease and 34 patients who had previously been treated or who had a preexisting low-grade lymphoma, according to the level of expression of 100 genes. Red areas indicate increased expression, and green areas decreased expression. Each column represents a single diffuse large-B-cell lymphoma, and each row represents a single gene. Genes that are characteristically expressed in germinal-center B-cell-like diffuse large-B-cell lymphomas or activated B-cell-like diffuse large-B-cell lymphomas are indicated. The dendrogram at the top shows the degree to which each diffuse large-B-cell lymphoma is related to the others with respect to gene expression. Panel B shows the number of samples with amplification of the c-rel locus and bcl-2 translocations in subgroups of diffuse large-B-cell lymphoma. The ratio of genomic copy number for the c-rel and {beta}2-microglobulin loci was determined by a quantitative polymerase-chain-reaction assay, and ratios greater than 2 were considered to indicate c-rel amplification. The bcl-2 translocations were detected with the use of a polymerase-chain-reaction assay for the main break-point cluster region that is frequently involved in the t(14;18) translocation. Data are from patients who had untreated diffuse large-B-cell lymphomas without preexisting cancer. Panel C shows Kaplan-Meier estimates of overall survival after chemotherapy among the 240 previously untreated patients, according to the gene-expression subgroup. Rosenwald A et al. N Engl J Med 2002;346:1937-1947

Brutons kinase

Brutons kinase Ibrutinib

Gen-expressie profiel DLBC-NHL Figure 1. Subgroups of Diffuse Large-B-Cell Lymphoma According to Gene-Expression Profiles. Panel A shows the hierarchical clustering of diffuse large-B-cell lymphomas from 240 patients with untreated disease and 34 patients who had previously been treated or who had a preexisting low-grade lymphoma, according to the level of expression of 100 genes. Red areas indicate increased expression, and green areas decreased expression. Each column represents a single diffuse large-B-cell lymphoma, and each row represents a single gene. Genes that are characteristically expressed in germinal-center B-cell-like diffuse large-B-cell lymphomas or activated B-cell-like diffuse large-B-cell lymphomas are indicated. The dendrogram at the top shows the degree to which each diffuse large-B-cell lymphoma is related to the others with respect to gene expression. Panel B shows the number of samples with amplification of the c-rel locus and bcl-2 translocations in subgroups of diffuse large-B-cell lymphoma. The ratio of genomic copy number for the c-rel and {beta}2-microglobulin loci was determined by a quantitative polymerase-chain-reaction assay, and ratios greater than 2 were considered to indicate c-rel amplification. The bcl-2 translocations were detected with the use of a polymerase-chain-reaction assay for the main break-point cluster region that is frequently involved in the t(14;18) translocation. Data are from patients who had untreated diffuse large-B-cell lymphomas without preexisting cancer. Panel C shows Kaplan-Meier estimates of overall survival after chemotherapy among the 240 previously untreated patients, according to the gene-expression subgroup. R-CHOP-21 R-CHOP-21 + Ibrutinib

Intermediar NHL Stadium 1: 3 x R-CHOP-21 + IN-RTX Stadium 2-4 Germinal-center type: R-CHOP intraveneus vs subcutaan (MabEase) Stadium 2-4 non-Germinal center type: R-CHOP-21 vs R-CHOP-21 + Ibrutinib Figure 2. Development of the Six-Gene Model. Panel A shows Kaplan-Meier estimates of overall survival in the 66 patients with diffuse large-B-cell lymphoma, analyzed by quantitative reverse-transcriptase polymerase chain reaction with TaqMan probe-based assays. The dotted lines represent 95 percent confidence intervals. Panel B shows Kaplan-Meier curves for overall survival in the three groups (at low, medium, and high risk of death) as defined by a prediction model based on the weighted expression of six genes (LMO2, BCL6, FN1, CCND2, SCYA3, and BCL2). According to log-likelihood estimates, P=0.001 for the model based on a continuous variable, and P=0.02 for the model based on the three discrete groups shown in the figure.

Non-Hodgkin lymfoom Vragen?